Switch to:
Also traded in: Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 157.61
OPHLY's Cash to Debt is ranked higher than
67% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. OPHLY: 157.61 )
Ranked among companies with meaningful Cash to Debt only.
OPHLY' s Cash to Debt Range Over the Past 10 Years
Min: 136.13  Med: 3387.13 Max: 9689.92
Current: 157.61
136.13
9689.92
Equity to Asset 0.87
OPHLY's Equity to Asset is ranked higher than
89% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. OPHLY: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
OPHLY' s Equity to Asset Range Over the Past 10 Years
Min: 0.87  Med: 0.90 Max: 0.93
Current: 0.87
0.87
0.93
Interest Coverage 90.53
OPHLY's Interest Coverage is ranked higher than
66% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. OPHLY: 90.53 )
Ranked among companies with meaningful Interest Coverage only.
OPHLY' s Interest Coverage Range Over the Past 10 Years
Min: 104.84  Med: 9999.00 Max: 9999.99
Current: 90.53
104.84
9999.99
F-Score: 4
Z-Score: 19.89
M-Score: -2.38
WACC vs ROIC
5.65%
6.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 19.03
OPHLY's Operating margin (%) is ranked higher than
81% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. OPHLY: 19.03 )
Ranked among companies with meaningful Operating margin (%) only.
OPHLY' s Operating margin (%) Range Over the Past 10 Years
Min: 10.9  Med: 26.01 Max: 37.29
Current: 19.03
10.9
37.29
Net-margin (%) 15.60
OPHLY's Net-margin (%) is ranked higher than
82% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. OPHLY: 15.60 )
Ranked among companies with meaningful Net-margin (%) only.
OPHLY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.73  Med: 17.24 Max: 24.89
Current: 15.6
9.73
24.89
ROE (%) 5.29
OPHLY's ROE (%) is ranked lower than
56% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. OPHLY: 5.29 )
Ranked among companies with meaningful ROE (%) only.
OPHLY' s ROE (%) Range Over the Past 10 Years
Min: 2.76  Med: 5.92 Max: 8.05
Current: 5.29
2.76
8.05
ROA (%) 4.73
OPHLY's ROA (%) is ranked higher than
55% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. OPHLY: 4.73 )
Ranked among companies with meaningful ROA (%) only.
OPHLY' s ROA (%) Range Over the Past 10 Years
Min: 2.52  Med: 5.45 Max: 7.22
Current: 4.73
2.52
7.22
ROC (Joel Greenblatt) (%) 29.61
OPHLY's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. OPHLY: 29.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPHLY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.31  Med: 42.83 Max: 66.02
Current: 29.61
17.31
66.02
Revenue Growth (3Y)(%) -39.60
OPHLY's Revenue Growth (3Y)(%) is ranked lower than
95% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. OPHLY: -39.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPHLY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.6  Med: 0.70 Max: 5.7
Current: -39.6
-39.6
5.7
EBITDA Growth (3Y)(%) -40.20
OPHLY's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. OPHLY: -40.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPHLY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.2  Med: -8.80 Max: 3.2
Current: -40.2
-40.2
3.2
EPS Growth (3Y)(%) -40.80
OPHLY's EPS Growth (3Y)(%) is ranked lower than
91% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. OPHLY: -40.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPHLY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.7  Med: -5.40 Max: 64
Current: -40.8
-44.7
64
» OPHLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OPHLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OTSKY, OTCPK:KYKOF, OTCPK:ALPMY, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM, AMEX:TXMD, OTCPK:HAWPF, OTCPK:DCHPF, OTCPK:VEGPF, OTCPK:SKYEY, NAS:RTRX, OTCPK:ULIHF, OTCPK:ABSCF, NAS:AERI » details
Traded in other countries:4528.Japan,
ONO Pharmaceutical Co., Ltd., along with its subsidiaries is engaged in research & development, manufacturing and selling of medical and general pharmaceutical products.

Ono Pharmaceutical Co Ltd was incorporated in Japan on July 4, 1947. The Company along with its subsidiaries is engaged in research & development, manufacturing and selling of medical and general pharmaceutical products. Its product portfolio includes GLACTIV Tablets for the Treatment of Type 2 Diabetes; RECALBON Tablets for the Treatment of Osteoporosis; EMEND Capsules / PROEMEND for Intravenous Injection for the Treatment of Chemotherapy-induced Nausea and Vomiting, STAYBLA Tablets for the Treatment of Overactive Bladder; RIVASTACH Patch for the Treatment of Alzheimer's Disease; ORENCIA for Subcutaneous Injection for the Treatment of Rheumatoid Arthritis; FORXIGA Tablets for the Treatment of Type 2 Diabetes; OPALMON Tablets for the Treatment of Peripheral Circulatory Disorder; ONOACT for Intravenous Infusion for the Treatment of Tachyarrhythmia Intra-operative or Post-operative, or Tachyarrhythmia in Left Ventricular Dysfunction; and ELASPOL for Injection for the Treatment of Acute Lung Injury Associated with Systemic Inflammatory Response Syndrome. The Company has operations in geographical areas including; Japan, Europe, and Asia.

Ratios

vs
industry
vs
history
P/E(ttm) 421.76
OPHLY's P/E(ttm) is ranked lower than
98% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. OPHLY: 421.76 )
Ranked among companies with meaningful P/E(ttm) only.
OPHLY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.26  Med: 26.95 Max: 574.75
Current: 421.76
12.26
574.75
PE(NRI) 421.31
OPHLY's PE(NRI) is ranked lower than
97% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. OPHLY: 421.31 )
Ranked among companies with meaningful PE(NRI) only.
OPHLY' s PE(NRI) Range Over the Past 10 Years
Min: 2.59  Med: 26.96 Max: 574.29
Current: 421.31
2.59
574.29
Price/Owner Earnings (ttm) 1847.05
OPHLY's Price/Owner Earnings (ttm) is ranked lower than
99% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. OPHLY: 1847.05 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
OPHLY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.76  Med: 52.85 Max: 2414.23
Current: 1847.05
15.76
2414.23
P/B 4.47
OPHLY's P/B is ranked lower than
68% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. OPHLY: 4.47 )
Ranked among companies with meaningful P/B only.
OPHLY' s P/B Range Over the Past 10 Years
Min: 0.94  Med: 1.34 Max: 5.84
Current: 4.47
0.94
5.84
P/S 17.26
OPHLY's P/S is ranked lower than
88% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. OPHLY: 17.26 )
Ranked among companies with meaningful P/S only.
OPHLY' s P/S Range Over the Past 10 Years
Min: 2.85  Med: 4.04 Max: 22.56
Current: 17.26
2.85
22.56
POCF 310.80
OPHLY's POCF is ranked lower than
98% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. OPHLY: 310.80 )
Ranked among companies with meaningful POCF only.
OPHLY' s POCF Range Over the Past 10 Years
Min: 14.2  Med: 31.28 Max: 406.24
Current: 310.8
14.2
406.24
EV-to-EBIT 57.30
OPHLY's EV-to-EBIT is ranked lower than
87% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. OPHLY: 57.30 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 12.40 Max: 405.7
Current: 57.3
4.1
405.7
EV-to-EBITDA 47.97
OPHLY's EV-to-EBITDA is ranked lower than
86% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. OPHLY: 47.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 11.85 Max: 339.6
Current: 47.97
3.1
339.6
Current Ratio 4.28
OPHLY's Current Ratio is ranked higher than
72% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. OPHLY: 4.28 )
Ranked among companies with meaningful Current Ratio only.
OPHLY' s Current Ratio Range Over the Past 10 Years
Min: 4.28  Med: 7.07 Max: 7.76
Current: 4.28
4.28
7.76
Quick Ratio 3.84
OPHLY's Quick Ratio is ranked higher than
75% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. OPHLY: 3.84 )
Ranked among companies with meaningful Quick Ratio only.
OPHLY' s Quick Ratio Range Over the Past 10 Years
Min: 3.84  Med: 6.58 Max: 7.13
Current: 3.84
3.84
7.13
Days Inventory 216.63
OPHLY's Days Inventory is ranked lower than
84% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. OPHLY: 216.63 )
Ranked among companies with meaningful Days Inventory only.
OPHLY' s Days Inventory Range Over the Past 10 Years
Min: 161.39  Med: 209.74 Max: 273.08
Current: 216.63
161.39
273.08

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.86
OPHLY's Dividend Yield is ranked higher than
76% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. OPHLY: 0.86 )
Ranked among companies with meaningful Dividend Yield only.
OPHLY' s Dividend Yield Range Over the Past 10 Years
Min: 0.83  Med: 2.58 Max: 5.3
Current: 0.86
0.83
5.3
Dividend Payout 3.95
OPHLY's Dividend Payout is ranked lower than
97% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. OPHLY: 3.95 )
Ranked among companies with meaningful Dividend Payout only.
OPHLY' s Dividend Payout Range Over the Past 10 Years
Min: 0.35  Med: 0.87 Max: 11.46
Current: 3.95
0.35
11.46
Dividend Growth (3y) 44.20
OPHLY's Dividend Growth (3y) is ranked higher than
94% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. OPHLY: 44.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
OPHLY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 44.2
Current: 44.2
0
44.2
Forward Dividend Yield 0.94
OPHLY's Forward Dividend Yield is ranked higher than
75% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. OPHLY: 0.94 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.86
OPHLY's Yield on cost (5-Year) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. OPHLY: 1.86 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
OPHLY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.82  Med: 5.57 Max: 11.62
Current: 1.86
1.82
11.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.00
OPHLY's Price/Net Cash is ranked lower than
78% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.32 vs. OPHLY: 33.00 )
Ranked among companies with meaningful Price/Net Cash only.
OPHLY' s Price/Net Cash Range Over the Past 10 Years
Min: 4.68  Med: 8.38 Max: 39.58
Current: 33
4.68
39.58
Price/Net Current Asset Value 13.63
OPHLY's Price/Net Current Asset Value is ranked lower than
73% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. OPHLY: 13.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPHLY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.74  Med: 4.39 Max: 16.35
Current: 13.63
2.74
16.35
Price/Tangible Book 4.86
OPHLY's Price/Tangible Book is ranked lower than
62% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. OPHLY: 4.86 )
Ranked among companies with meaningful Price/Tangible Book only.
OPHLY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 1.45 Max: 5.83
Current: 4.86
1.11
5.83
Price/Projected FCF 22.23
OPHLY's Price/Projected FCF is ranked lower than
91% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. OPHLY: 22.23 )
Ranked among companies with meaningful Price/Projected FCF only.
OPHLY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.88  Med: 2.86 Max: 26.66
Current: 22.23
1.88
26.66
Price/Median PS Value 4.29
OPHLY's Price/Median PS Value is ranked lower than
94% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. OPHLY: 4.29 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHLY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1.05 Max: 5.15
Current: 4.29
0.81
5.15
Price/Graham Number 9.55
OPHLY's Price/Graham Number is ranked lower than
94% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. OPHLY: 9.55 )
Ranked among companies with meaningful Price/Graham Number only.
OPHLY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.9  Med: 1.28 Max: 11.45
Current: 9.55
0.9
11.45
Earnings Yield (Greenblatt) (%) 1.70
OPHLY's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. OPHLY: 1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHLY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 8.05 Max: 24.3
Current: 1.7
0.2
24.3
Forward Rate of Return (Yacktman) (%) -4.06
OPHLY's Forward Rate of Return (Yacktman) (%) is ranked lower than
71% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. OPHLY: -4.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OPHLY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.3  Med: -1.90 Max: 15.5
Current: -4.06
-14.3
15.5

More Statistics

Revenue (TTM) (Mil) $1,347
EPS (TTM) $ 0.02
Beta0.52
Short Percentage of Float0.00%
52-Week Range $7.58 - 21.45
Shares Outstanding (Mil)1,590.28

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)